Erythropoietin in Predicting Prognosis in Patients with Acute-on-Chronic Liver Failure
Samo za registrovane korisnike
2016
Autori
Alempijević, TamaraZec, Simon
Nikolić, Vladimir
Veljković, Aleksandar
Milivojević, Vladimir
Dopsaj, Violeta
Stanković, Sanja
Milosavljević, Tomica
Članak u časopisu (Objavljena verzija)
Metapodaci
Prikaz svih podataka o dokumentuApstrakt
Background & Aims: Acute-on-chronic liver failure (ACLF) is characterized by a rapid progression to multiple organ failure and is associated with a very high mortality rate of 50-90%. Novel therapies are being investigated such as Erythropoietin (EPO). The aim of this prospective cohort study was to analyse the value of EPO in predicting prognosis and determine which patients may benefit most from EPO therapy. Methods: According to the EASL-CLIF criteria, 104 consecutive patients were diagnosed with ACLF, and separated into two groups based on the type of insult: bleeding (Group A=31) or non-bleeding (Group B=73). In addition to a complete biochemical work-up and calculation of relevant prognostic scores, levels of EPO were measured on admission and correlated to the type of insult and final outcome. Results: Fifteen patients from Group A (mean age 60.32 +/- 9.29 years) had a lethal outcome and higher values of EPO on admission (319.26 +/- 326.58 mIU/ml) (p lt 0.005), compared to the 3...7 patients from Group B (mean age 59.9 +/- 10.19 years) with EPO levels at admission of 29.88 +/- 34.6 mIU/mL. In Group B, a cut-off EPO value of 30.65 mIU/mL had a sensitivity of 87.5% and a specificity 57.4% in predicting lethal outcome with an AUROC of 0.823. In Group A, a cut-off value of 229.95 mlU/mL had a sensitivity and specificity of 53.3% and 92.7%, respectively. The AUROC for this cut-off was 0.847. Conclusions: Erythropoietin is superior to the standard prognostic scores in predicting 28-day mortality. Lower levels of EPO were detected in patients without bleeding as an insult indicating a possible therapeutic benefit in these patients.
Izvor:
Journal of Gastrointestinal and Liver Diseases, 2016, 25, 4, 473-479Izdavač:
- Medical Univ Press, Cluj-Napoca
DOI: 10.15403/jgld.2014.1121.254.jev
ISSN: 1841-8724
PubMed: 27981303
WoS: 000391085100009
Scopus: 2-s2.0-85006367242
Institucija/grupa
PharmacyTY - JOUR AU - Alempijević, Tamara AU - Zec, Simon AU - Nikolić, Vladimir AU - Veljković, Aleksandar AU - Milivojević, Vladimir AU - Dopsaj, Violeta AU - Stanković, Sanja AU - Milosavljević, Tomica PY - 2016 UR - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2670 AB - Background & Aims: Acute-on-chronic liver failure (ACLF) is characterized by a rapid progression to multiple organ failure and is associated with a very high mortality rate of 50-90%. Novel therapies are being investigated such as Erythropoietin (EPO). The aim of this prospective cohort study was to analyse the value of EPO in predicting prognosis and determine which patients may benefit most from EPO therapy. Methods: According to the EASL-CLIF criteria, 104 consecutive patients were diagnosed with ACLF, and separated into two groups based on the type of insult: bleeding (Group A=31) or non-bleeding (Group B=73). In addition to a complete biochemical work-up and calculation of relevant prognostic scores, levels of EPO were measured on admission and correlated to the type of insult and final outcome. Results: Fifteen patients from Group A (mean age 60.32 +/- 9.29 years) had a lethal outcome and higher values of EPO on admission (319.26 +/- 326.58 mIU/ml) (p lt 0.005), compared to the 37 patients from Group B (mean age 59.9 +/- 10.19 years) with EPO levels at admission of 29.88 +/- 34.6 mIU/mL. In Group B, a cut-off EPO value of 30.65 mIU/mL had a sensitivity of 87.5% and a specificity 57.4% in predicting lethal outcome with an AUROC of 0.823. In Group A, a cut-off value of 229.95 mlU/mL had a sensitivity and specificity of 53.3% and 92.7%, respectively. The AUROC for this cut-off was 0.847. Conclusions: Erythropoietin is superior to the standard prognostic scores in predicting 28-day mortality. Lower levels of EPO were detected in patients without bleeding as an insult indicating a possible therapeutic benefit in these patients. PB - Medical Univ Press, Cluj-Napoca T2 - Journal of Gastrointestinal and Liver Diseases T1 - Erythropoietin in Predicting Prognosis in Patients with Acute-on-Chronic Liver Failure VL - 25 IS - 4 SP - 473 EP - 479 DO - 10.15403/jgld.2014.1121.254.jev ER -
@article{ author = "Alempijević, Tamara and Zec, Simon and Nikolić, Vladimir and Veljković, Aleksandar and Milivojević, Vladimir and Dopsaj, Violeta and Stanković, Sanja and Milosavljević, Tomica", year = "2016", abstract = "Background & Aims: Acute-on-chronic liver failure (ACLF) is characterized by a rapid progression to multiple organ failure and is associated with a very high mortality rate of 50-90%. Novel therapies are being investigated such as Erythropoietin (EPO). The aim of this prospective cohort study was to analyse the value of EPO in predicting prognosis and determine which patients may benefit most from EPO therapy. Methods: According to the EASL-CLIF criteria, 104 consecutive patients were diagnosed with ACLF, and separated into two groups based on the type of insult: bleeding (Group A=31) or non-bleeding (Group B=73). In addition to a complete biochemical work-up and calculation of relevant prognostic scores, levels of EPO were measured on admission and correlated to the type of insult and final outcome. Results: Fifteen patients from Group A (mean age 60.32 +/- 9.29 years) had a lethal outcome and higher values of EPO on admission (319.26 +/- 326.58 mIU/ml) (p lt 0.005), compared to the 37 patients from Group B (mean age 59.9 +/- 10.19 years) with EPO levels at admission of 29.88 +/- 34.6 mIU/mL. In Group B, a cut-off EPO value of 30.65 mIU/mL had a sensitivity of 87.5% and a specificity 57.4% in predicting lethal outcome with an AUROC of 0.823. In Group A, a cut-off value of 229.95 mlU/mL had a sensitivity and specificity of 53.3% and 92.7%, respectively. The AUROC for this cut-off was 0.847. Conclusions: Erythropoietin is superior to the standard prognostic scores in predicting 28-day mortality. Lower levels of EPO were detected in patients without bleeding as an insult indicating a possible therapeutic benefit in these patients.", publisher = "Medical Univ Press, Cluj-Napoca", journal = "Journal of Gastrointestinal and Liver Diseases", title = "Erythropoietin in Predicting Prognosis in Patients with Acute-on-Chronic Liver Failure", volume = "25", number = "4", pages = "473-479", doi = "10.15403/jgld.2014.1121.254.jev" }
Alempijević, T., Zec, S., Nikolić, V., Veljković, A., Milivojević, V., Dopsaj, V., Stanković, S.,& Milosavljević, T.. (2016). Erythropoietin in Predicting Prognosis in Patients with Acute-on-Chronic Liver Failure. in Journal of Gastrointestinal and Liver Diseases Medical Univ Press, Cluj-Napoca., 25(4), 473-479. https://doi.org/10.15403/jgld.2014.1121.254.jev
Alempijević T, Zec S, Nikolić V, Veljković A, Milivojević V, Dopsaj V, Stanković S, Milosavljević T. Erythropoietin in Predicting Prognosis in Patients with Acute-on-Chronic Liver Failure. in Journal of Gastrointestinal and Liver Diseases. 2016;25(4):473-479. doi:10.15403/jgld.2014.1121.254.jev .
Alempijević, Tamara, Zec, Simon, Nikolić, Vladimir, Veljković, Aleksandar, Milivojević, Vladimir, Dopsaj, Violeta, Stanković, Sanja, Milosavljević, Tomica, "Erythropoietin in Predicting Prognosis in Patients with Acute-on-Chronic Liver Failure" in Journal of Gastrointestinal and Liver Diseases, 25, no. 4 (2016):473-479, https://doi.org/10.15403/jgld.2014.1121.254.jev . .